The FibroGENE® lab test, only a concept for the last few years, is now ready for development for practical use as a decision support biomarker test that could greatly impact health care by allowing physicians to identify the cause of patient disease symptoms and select appropriate treatment more precisely.
AMPEL BioSolutions’ Breakthrough Predicts Drug Options for Fibromyalgia
The FibroGENE® lab test, only a concept for the last few years, is now ready for development for practical use as a decision support biomarker test that could greatly impact health care by allowing physicians to identify the cause of patient disease symptoms and select appropriate treatment more precisely.
AMPEL BioSolutions’ Breakthrough Predicts Drug Options for Fibromyalgia
Paired with AMPEL’s pipeline of tools to analyze very large and complex clinical datasets (“Big Data”), FibroGENE® is a significant step towards implementing a routine test for monitoring fibromyalgia and providing decision support for treatment based on a patient’s gene expression. This will transform the way doctors treat fibromyalgia by using the information gathered by the lab test and analyzed by bioinformatics to characterize the precise molecular abnormalities and treat symptoms, reduce pain and increase the quality of life of millions of Americans.
AMPEL BioSolutions, Duke Researchers Establish Fibromyalgia Gene Signature
Precision medicine company AMPEL BioSolutions and academic partners at Duke University identified two distinct gene signatures for systemic lupus erythematosus (SLE), one of which appears specific to patients experiencing fibromyalgia.
New Blood Test to Help Physicians Prevent Major Cardiovascular Events in Women with Lupus
Now, a genetic precision medicine test for lupus patients could save lives by predicting heart disease before it happens and providing decision support for prophylactic therapies.
Lupus, coronary artery disease share genetic risk factors; data may lead to early testing
Researchers have identified shared genetic risk factors for systemic lupus erythematosus and coronary artery disease, according to data published in Cell Reports Medicine.